CN105745543B - 卵巢癌的自身抗体生物标志物 - Google Patents

卵巢癌的自身抗体生物标志物 Download PDF

Info

Publication number
CN105745543B
CN105745543B CN201480063118.7A CN201480063118A CN105745543B CN 105745543 B CN105745543 B CN 105745543B CN 201480063118 A CN201480063118 A CN 201480063118A CN 105745543 B CN105745543 B CN 105745543B
Authority
CN
China
Prior art keywords
autoantibody
oophoroma
purposes
autoantibodies
anxa1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480063118.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105745543A (zh
Inventor
P·霍夫曼
M·奥伊赫勒
K·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADELAIDE RESEARCH and INNOVATION Pty Ltd
Original Assignee
ADELAIDE RESEARCH and INNOVATION Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013903595A external-priority patent/AU2013903595A0/en
Application filed by ADELAIDE RESEARCH and INNOVATION Pty Ltd filed Critical ADELAIDE RESEARCH and INNOVATION Pty Ltd
Publication of CN105745543A publication Critical patent/CN105745543A/zh
Application granted granted Critical
Publication of CN105745543B publication Critical patent/CN105745543B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480063118.7A 2013-09-18 2014-09-18 卵巢癌的自身抗体生物标志物 Active CN105745543B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013903595 2013-09-18
AU2013903595A AU2013903595A0 (en) 2013-09-18 Autoantibody biomarkers of ovarian cancer
PCT/AU2014/000925 WO2015039175A1 (en) 2013-09-18 2014-09-18 Autoantibody biomarkers of ovarian cancer

Publications (2)

Publication Number Publication Date
CN105745543A CN105745543A (zh) 2016-07-06
CN105745543B true CN105745543B (zh) 2018-02-02

Family

ID=52687999

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480063118.7A Active CN105745543B (zh) 2013-09-18 2014-09-18 卵巢癌的自身抗体生物标志物

Country Status (7)

Country Link
US (3) US20160291025A1 (enExample)
EP (1) EP3047277B1 (enExample)
JP (1) JP6588893B2 (enExample)
CN (1) CN105745543B (enExample)
AU (1) AU2014324080B2 (enExample)
CA (1) CA2924600A1 (enExample)
WO (1) WO2015039175A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107056888A (zh) * 2017-03-01 2017-08-18 中山大学肿瘤防治中心 Atp1a1靶向多肽及应用
CN109116024B (zh) * 2018-06-14 2021-04-23 郑州大学第一附属医院 一种肺癌标志物抗-actr3自身抗体及其应用
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
CN113785199B (zh) * 2019-03-01 2024-02-09 先进标志物探索公司 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征
AU2020368546A1 (en) * 2019-10-16 2022-05-26 Icahn School Of Medicine At Mount Sinai Systems and methods for detecting a disease condition
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1675372A (zh) * 2002-08-06 2005-09-28 约翰霍普金斯大学 用于检测卵巢癌的生物标记的用途
CN101268367A (zh) * 2005-06-24 2008-09-17 赛弗吉生物系统公司 卵巢癌的生物标记
WO2008115710A2 (en) * 2007-03-07 2008-09-25 The Johns Hopkins University Biomarkers for cancer
US20080300141A1 (en) * 2001-12-04 2008-12-04 Michael Tainsky Neoepitope Detection of Disease Using Protein Arrays
CN101410715A (zh) * 2006-01-27 2009-04-15 三路影像公司 鉴定患卵巢癌的可能性增加的患者的方法及其组合物
CN101762699A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法
CN101855553A (zh) * 2007-06-29 2010-10-06 科里罗吉克系统公司 卵巢癌的预测标记
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161262B1 (en) * 1999-03-15 2008-05-21 University of Maryland, Baltimore SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20020037286A1 (en) * 2000-04-03 2002-03-28 Matthias Krause Methods for altering T cell and macrophage activation
AU2007297310B2 (en) 2006-09-13 2013-11-07 Oncimmune Limited Improved immunoassay methods
JP5265140B2 (ja) * 2007-06-14 2013-08-14 学校法人日本医科大学 卵巣癌の検出方法及び検出用キット
RU2571687C2 (ru) * 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
EP2277049A4 (en) * 2008-05-09 2012-05-30 Univ Duke AUTOANTIKÖRPER FOR THE PROOF AND THE TREATMENT OF CANCER
US20120046181A1 (en) * 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
US20120004289A1 (en) * 2009-03-06 2012-01-05 The Johns Hopkins University Annexin a11 and associated genes as biomarkers for cancer
US20120277326A1 (en) 2009-11-20 2012-11-01 Taylor Douglas D Biomarkers of cancer
JP2011257147A (ja) * 2010-06-04 2011-12-22 Nitto Boseki Co Ltd データ収集方法、キット及び腫瘍マーカー
WO2013112801A1 (en) * 2012-01-26 2013-08-01 Ibc Pharmaceuticals, Inc. Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
JP5574348B2 (ja) * 2012-05-31 2014-08-20 国立大学法人 千葉大学 肺サルコイドーシスおよび眼サルコイドーシスの検出マーカー及び検出キット
US20140179808A1 (en) * 2012-10-23 2014-06-26 Bio-Rad Laboratories, Inc. Detection of Ovarian Carcinoma by Assay for Autoantibodies to Multiple Antigens
EP2951592A4 (en) 2013-01-31 2017-01-04 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Autoantibody signature for the early detection of ovarian cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300141A1 (en) * 2001-12-04 2008-12-04 Michael Tainsky Neoepitope Detection of Disease Using Protein Arrays
CN1675372A (zh) * 2002-08-06 2005-09-28 约翰霍普金斯大学 用于检测卵巢癌的生物标记的用途
CN101268367A (zh) * 2005-06-24 2008-09-17 赛弗吉生物系统公司 卵巢癌的生物标记
CN101410715A (zh) * 2006-01-27 2009-04-15 三路影像公司 鉴定患卵巢癌的可能性增加的患者的方法及其组合物
WO2008115710A2 (en) * 2007-03-07 2008-09-25 The Johns Hopkins University Biomarkers for cancer
CN101855553A (zh) * 2007-06-29 2010-10-06 科里罗吉克系统公司 卵巢癌的预测标记
CN101762699A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中肿瘤相关抗原125的磁性免疫层析试纸条及制备方法
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Technical validation of an autoantibody test for lung cancer;A. Murray et al;《Annals of Oncology》;20100202;第21卷(第8期);第1687－1688页 *

Also Published As

Publication number Publication date
US20220365088A1 (en) 2022-11-17
WO2015039175A1 (en) 2015-03-26
US12287337B2 (en) 2025-04-29
CN105745543A (zh) 2016-07-06
US20160291025A1 (en) 2016-10-06
JP2016536568A (ja) 2016-11-24
AU2014324080B2 (en) 2020-07-23
EP3047277A1 (en) 2016-07-27
US20190219584A1 (en) 2019-07-18
EP3047277A4 (en) 2017-05-10
CA2924600A1 (en) 2015-03-26
JP6588893B2 (ja) 2019-10-09
AU2014324080A1 (en) 2016-04-14
EP3047277B1 (en) 2018-11-21
US11371993B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
CN105745543B (zh) 卵巢癌的自身抗体生物标志物
JP6636016B2 (ja) 抗ｂ７−ｈ３抗体及びその診断用途
JP6666905B2 (ja) Ｐｄ−ｌ１抗体及びその使用
ES2745014T3 (es) Proteína
Liu et al. Calreticulin as a potential diagnostic biomarker for lung cancer
Chen et al. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia
US8540998B2 (en) Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
JP5669757B2 (ja) 精巣癌診断および予後診断におけるｒｂｍ３タンパク質
US20190202930A1 (en) Methods for treatment of ovarian cancer
US8420091B2 (en) Matriptase protein and uses thereof
KR20170137848A (ko) 폐암을 치료하는 방법
JP2012511894A (ja) Ｐｔａ０７２タンパク質
US8652478B2 (en) Method for treating cancer by administering antibody to ephrin type-A receptor 7
KR20230165283A (ko) 암을 위한 바이오마커 및 요법 표적으로서의 시트룰린화된 단백질
US20120058131A1 (en) Pta089 protein
Shively et al. The XXXIVth Meeting of the International Society for Oncodevelopmental Biology and Medicine, ISOBM 2006 September 16–20, 2006, Pasadena, Calif.
WO2012024643A2 (en) MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant